[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1207296A1 - Genotype- or phenotype-based drug formulation - Google Patents

Genotype- or phenotype-based drug formulation

Info

Publication number
HK1207296A1
HK1207296A1 HK15107896.3A HK15107896A HK1207296A1 HK 1207296 A1 HK1207296 A1 HK 1207296A1 HK 15107896 A HK15107896 A HK 15107896A HK 1207296 A1 HK1207296 A1 HK 1207296A1
Authority
HK
Hong Kong
Prior art keywords
genotype
phenotype
drug formulation
based drug
formulation
Prior art date
Application number
HK15107896.3A
Other languages
English (en)
Chinese (zh)
Inventor
Stefan Willmann
Thomas Eiing
Kristin Dickschen
Original Assignee
Bayer Technology Services Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Technology Services Gmbh filed Critical Bayer Technology Services Gmbh
Publication of HK1207296A1 publication Critical patent/HK1207296A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15107896.3A 2012-06-01 2015-08-17 Genotype- or phenotype-based drug formulation HK1207296A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
PCT/EP2013/060824 WO2013178565A1 (de) 2012-06-01 2013-05-27 Genotyp- bzw. phänotyp-basierte arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
HK1207296A1 true HK1207296A1 (en) 2016-01-29

Family

ID=48520964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107896.3A HK1207296A1 (en) 2012-06-01 2015-08-17 Genotype- or phenotype-based drug formulation

Country Status (23)

Country Link
US (3) US10285958B2 (da)
EP (2) EP2668945A1 (da)
JP (2) JP6096289B2 (da)
KR (1) KR102129043B1 (da)
CN (2) CN110075097A (da)
AR (2) AR091234A1 (da)
AU (1) AU2013269793B2 (da)
BR (1) BR112014030059B1 (da)
CA (1) CA2875189C (da)
DK (1) DK2854789T3 (da)
ES (1) ES2744306T3 (da)
HK (1) HK1207296A1 (da)
HU (1) HUE045699T2 (da)
IL (1) IL235988B (da)
MX (1) MX370304B (da)
NZ (1) NZ702849A (da)
PL (1) PL2854789T3 (da)
PT (1) PT2854789T (da)
RU (1) RU2683260C2 (da)
SA (1) SA113340607B1 (da)
SG (2) SG10201610072UA (da)
TW (1) TWI644666B (da)
WO (1) WO2013178565A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) * 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
WO2001053460A1 (en) 2000-01-21 2001-07-26 Variagenics, Inc. Identification of genetic components of drug response
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
US7169813B2 (en) 2004-03-18 2007-01-30 Fondazione IRCCS “Istituto Nazionale Dei Tumori” 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
WO2005094363A2 (en) 2004-03-30 2005-10-13 New York University System, method and software arrangement for bi-allele haplotype phasing
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
KR20080013927A (ko) * 2005-06-02 2008-02-13 바이오베일 라보라토리즈 인터내셔널 에스알엘 벤라팍스의 하나 이상 형태의 개질 방출 조성물
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
WO2007035613A1 (en) 2005-09-19 2007-03-29 Bg Medicine, Inc. Correlation analysis of biological systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
US9333190B2 (en) 2006-11-21 2016-05-10 Jina Pharmaceuticals, Inc. Endoxifen compositions and methods
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CN102067142A (zh) 2008-02-26 2011-05-18 普渡研究基金会 用于患者基因分型的方法
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
WO2010002937A1 (en) 2008-06-30 2010-01-07 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
US20110136913A1 (en) * 2008-08-19 2011-06-09 Goetz Matthew P Assessing and treating breast cancer patients
EP2346428B1 (en) 2008-09-25 2019-11-06 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
US20120088247A1 (en) 2009-02-23 2012-04-12 Indian University Research & Technology Corporatio Materials and methods for treating patients with taxoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
JP2013536220A (ja) * 2010-08-26 2013-09-19 アイピーシーエー ラボラトリーズ リミテッド 血栓症または塞栓を治療または予防するための方法
US20120329762A1 (en) * 2011-06-27 2012-12-27 Ashok Kumar Anti-thrombotic compounds
CA2869296A1 (en) 2012-04-02 2013-10-10 Berg Llc Interrogatory cell-based assays and uses thereof
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
AU2013269793A1 (en) 2015-01-22
TWI644666B (zh) 2018-12-21
US20170326080A1 (en) 2017-11-16
SG11201407791VA (en) 2015-01-29
RU2014154140A (ru) 2016-07-27
BR112014030059A2 (pt) 2017-07-25
CN104507464A (zh) 2015-04-08
JP2015519350A (ja) 2015-07-09
PT2854789T (pt) 2019-09-18
EP2854789A1 (de) 2015-04-08
HUE045699T2 (hu) 2020-01-28
DK2854789T3 (da) 2019-09-16
MX2014014596A (es) 2015-03-03
CA2875189C (en) 2020-09-22
CA2875189A1 (en) 2013-12-05
IL235988A0 (en) 2015-01-29
EP2668945A1 (de) 2013-12-04
EP2854789B1 (de) 2019-06-26
PL2854789T3 (pl) 2019-12-31
NZ702849A (en) 2016-09-30
JP6096289B2 (ja) 2017-03-15
SA113340607B1 (ar) 2018-05-09
JP2017048234A (ja) 2017-03-09
US20170326081A1 (en) 2017-11-16
AR118842A2 (es) 2021-11-03
ES2744306T3 (es) 2020-02-24
KR102129043B1 (ko) 2020-07-01
RU2683260C2 (ru) 2019-03-27
KR20150022894A (ko) 2015-03-04
US10285958B2 (en) 2019-05-14
AU2013269793B2 (en) 2018-03-01
CN110075097A (zh) 2019-08-02
BR112014030059B1 (pt) 2022-12-06
TW201400109A (zh) 2014-01-01
WO2013178565A1 (de) 2013-12-05
MX370304B (es) 2019-12-09
SG10201610072UA (en) 2017-01-27
IL235988B (en) 2018-11-29
AR091234A1 (es) 2015-01-21
US20150174082A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
HK1208372A1 (en) Liquid formulation
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1202445A1 (en) New formulation
HK1205146A1 (en) Pharmaceutical formulation
ZA201306000B (en) Stable formulation
HK1205679A1 (en) Nicotine formulation
HK1205683A1 (en) Pharmaceutical formulation having improved stability
LT3473255T (lt) Farmacinė vaisto forma, apimanti ciklezonidą
EP2822599A4 (en) VACCINE
ZA201502987B (en) Pharmaceutical composition
HK1207296A1 (en) Genotype- or phenotype-based drug formulation
HK1206269A1 (en) Pharmaceutical formulation comprising bendamustine
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
SG11201406097SA (en) Capsule formulation
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
HK1209339A1 (en) Pharmaceutical formulations
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL244316A0 (en) A new composition of a drug
GB201211247D0 (en) Improved formulation
IL234771B (en) Nicotine formulation
ZA201400751B (en) Pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations